SEATTLE, Oct. 25, 2016 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced that the company will present data evaluating its mRNA Hybrid Technology platform at the 4th International mRNA Health Conference taking place November 1-2, 2016 in Boston. The poster, titled, 'Targeted mRNA delivery to the liver for Intracellular Enyzme Replacement Therapy (i-ERT)' will be presented by Pierrot Harvie, Ph.D., Associate Director of Formulations at PhaseRx. The poster will be in session 6 at the Westin Boston Waterfront, 425 Summer Street, Boston, MA.
About PhaseRx
PhaseRx is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform and is applicable to a significant number of inherited liver diseases. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.
Contacts:
Company Contact:
Erin Cox
PhaseRx, Inc.
Director of Investor Relations
erin@phaserx.com
206.805.6306
Media Contact:
Jason Spark
Canale Communications
Senior Vice President
jason@canalecomm.com
619-849-6005
Investor Contact:
Robert H. Uhl
Westwicke Partners, LLC
Managing Director
robert.uhl@westwicke.com
858.356.5932
Logo - http://photos.prnewswire.com/prnh/20160802/395011LOGO
SOURCE PhaseRx, Inc.